



AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

February 17, 2026

MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 17, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM lung disease caused by *M. abscessus* and melioidosis, along with programs focused on targets in oncology and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes. For more information, please visit our website at www.an2therapeutics.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260217634495/en/>

COMPANY CONTACT:

Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge
ir@an2therapeutics.com

Source: AN2 Therapeutics, Inc.